To evaluate the safety and tolerability of combined administration of VSV injection solutions carrying different targets via multiple routes for treating advanced malignant solid tumors.
Voluntarily sign the informed consent form, understand this study, and agree to comply with the protocol and complete all trial procedures
Be at least 18 years of age at the time of signing the ICF, with no gender restrictions.
Patients with advanced solid tumors confirmed by histopathological/cytological examination of primary and/or metastatic lesions.
Patients who have failed standard therapy, lack a standard last-line treatment option, or are medically ineligible for standard therapy.
Subjects with other active malignancies within the past 5 years. Exceptions include subjects who have achieved complete remission and require no follow-up treatment, and subjects with malignancies within the scope of the indication.
Lesions intended for injection with a maximum diameter >100 mm；
Subjects who have participated in or are currently participating in other drug or medical device clinical trials within the past 4 weeks；
Subjects scheduled for or who have previously undergone tissue/organ transplantation；